|
LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM). |
|
|
Consulting or Advisory Role - Angiochem; Genentech/Roche; GERON; Kadmon; Lilly; Merrimack; Nektar; Novartis; Sanofi; to-BBB technologies BV |
Research Funding - Angiochem (Inst); Cascadian Therapeutics (Inst); Geron (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Oncothyreon (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tesaro (Inst); to-BBB technologies BV (Inst) |
Patents, Royalties, Other Intellectual Property - Jones and Bartlell; Up to Date.com |
|
|
No Relationships to Disclose |
|
Amanda Elyse Day Van Swearingen |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GeneCentric |
Consulting or Advisory Role - GeneCentric |
Patents, Royalties, Other Intellectual Property - I hold several diagnostic patents or pending patents in the area of solid tumor diagnostics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer (Inst); Cerulean Pharma (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - numerous at UNC (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - 17-0036 Smart Imaging Protocoling (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Genentech/Roche |
Consulting or Advisory Role - Genentech/Roche; Novartis; Peregrine Pharmaceuticals; Pfizer; Puma Biotechnology |
Research Funding - Celgene; Corcept Therapeutics; Merck |
|
|
Research Funding - Abbvie (Inst); Nektar (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Astellas Pharma; Genentech/Roche |
|
|
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst) |